Vanguard Investments Australia
CAPR icon

Vanguard Investments Australia’s Capricor Therapeutics CAPR Stock Holding History

Vanguard Investments Australia’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Hold
12,969
– – ﹤0.01% 1912
2026
Q1 		$394K Buy
+12,969
New +$346K ﹤0.01% 1696

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Investments Australia's CAPR Position: Q2 2026 in Review

Vanguard Investments Australia held its Capricor Therapeutics (CAPR) position steady in Q2 2026 at 12,969 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #1912.

Vanguard Investments Australia first reported a position in CAPR in Q1 2026 and has held it in 2 quarters since. The position peaked at $394K in Q1 2026. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Vanguard Investments Australia held 12,969 shares of Capricor Therapeutics worth $312K as of Q2 2026.
  • Vanguard Investments Australia left its Capricor Therapeutics share count unchanged in Q2 2026.
  • Capricor Therapeutics made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #1912 holding.
  • Vanguard Investments Australia first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Investments Australia's Capricor Therapeutics position peaked at $394K in Q1 2026.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.